---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-130553"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T18:40:02.484714+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enanta reports FY2024 revenue $67.6M, net loss $116M; RSV & immunology pipelines advance

## Summary
- Q4 revenue $14.6M (down 23% YoY); full-year $67.6M vs $79.2M due to lower MAVYRET royalties.
- Net loss Q4 $28.8M ($1.36/shr); full-year $116.0M ($5.48/shr) vs $133.8M prior year.
- Cash & securities $248.2M at Sept 30, 2024; runway expected into fiscal 2027.
- RSVPEDs zelicapavir Phase 2 topline data due December 2024; EDP-323 Phase 2a met endpoints (p<0.0001).
- Immunology expansion: KIT inhibitor EPS-1421 nominated; new STAT6 discovery program initiated.

## SEC filing metadata
- accession: 0000950170-24-130553
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/0000950170-24-130553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017024130553/enta-20241125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-130553
- JSON: https://secwatch.observer/filing/0000950170-24-130553.json
- Plain text: https://secwatch.observer/filing/0000950170-24-130553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.